Drug recall · July 1, 2020
Metformin Hydrochloride Extended-release Tablets USP recall
Why: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Metformin Hydrochloride Extended-release Tablets USP, 500 mg, 60 count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD Manufactured by: Lupin Limited Goa INDIA (NDC 68180-336-07)
- Lots / codes
Batch # G901203, exp. date 12/2020
- Quantity
- 6,540 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Product was distributed throughout the United States.
- Initiated
- June 11, 2020 · Voluntary: Firm initiated
- Classified
- June 20, 2020
- Reported
- July 1, 2020
- Ended
- December 23, 2021
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Metformin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.